Telehealth advocates have expressed support for the Drug Enforcement Administration’s (DEA) recent decision to extend the telemedicine flexibilities originally put in place during the COVID-19 pandemic. These provisions, which allow healthcare providers to prescribe certain controlled substances without an initial in-person consultation, have been extended for a third time, now set to continue through the end of 2025. More about this extension can be read on the DEA’s website.
While the continuity of these flexibilities is seen as crucial for maintaining healthcare accessibility, particularly in underserved areas, advocates are calling for the establishment of permanent regulations. During the period when new rules were proposed to roll back some of these flexibilities, the DEA received significant public input, with 38,000 comments submitted.
Kyle Zebley, senior vice president of public policy at the American Telemedicine Association, remarked on the relief provided by the extension, emphasizing that access to care for numerous patients could have been disrupted if the flexibilities had expired. He suggested a special registration process to address potential abuses while emphasizing that such cases have been minimal compared to the broader benefits of increased access.
Stephanie Strong, CEO of Boulder Care, also highlighted the need for permanent solutions. She noted that temporary measures are insufficient and advocated for advancements, including the potential impact of legislation such as the TREATS Act, aimed at solidifying these flexibilities for opioid use disorder treatments.
Eric Triana from Talkiatry highlighted the vital role telemedicine plays in bridging the gap in mental health services across the U.S., pointing out that a long-term framework is crucial. He anticipates that the Trump administration will work towards a robust regulation pathway that balances investigative needs with patient access.
The continued advocacy for telemedicine reflects broader trends in healthcare, where the digital transformation demands balancing innovation with regulatory oversight. Stakeholders remain optimistic that the coming years will see significant progress toward formalizing telemedicine’s role within the U.S. healthcare system.
For a deeper dive into the topic, view the full article at MedCity News.